Tecentriq 1,200 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCYX9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,910
Award facts
- Contract value 100% obligated
- $19,910.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $19,910.19 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Tecentriq 1,200 mg/20 mL vials. The award, issued on November 25, 2025, with an ultimate completion date of December 17, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the DLA's medical supply chain, fulfilling the diverse pharmaceutical requirements of Department of Defense healthcare operations globally. The company's portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with Tecentriq—an oncology treatment—representing one of several high-value pharmaceutical products the contractor regularly supplies to federal military medical facilities. As the sole awardee identified on this delivery order with no subcontractor relationships, DMS Pharmaceutical Group's established performance across multiple therapeutic categories and product lines positions it as a key regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy.
Quick answers
Who was awarded contract SPE2DR26FCYX9?
SPE2DR26FCYX9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FCYX9 worth?
The government has obligated $19,910 on SPE2DR26FCYX9.
Is contract SPE2DR26FCYX9 an order under another contract?
Yes. SPE2DR26FCYX9 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCYX9 competed?
The extent of competition for SPE2DR26FCYX9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award